Cocrystal Pharma Inc (COCP) Stock Price, Quote & News

Company Profile

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a cl...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 262 7123

Website: www.cocrystalpharma.com

Address:

19805 North Creek Parkway, Bothell, United States

bulmar Jun. 4 at 7:22 PM

$COCP New CEO and MARTIN still employed watching precious shareholder money get spent. He’s good at that.

0 · Reply

ms101 Jun. 4 at 2:54 PM

$COCP New CEO just dropped. Hassan's 3.5-year stealth mission is now live. Rerate of the century loading....

0 · Reply

elon_musk22 Jun. 3 at 1:48 PM

$COCP Significant the move to $25 begins

0 · Reply

Mohamedkheer Jun. 3 at 1:43 PM

$COCP

1 · Reply

DOUG_Called_It Jun. 3 at 1:22 PM

$COCP only reason you appoint new ceo is because people are not getting result… don’t catch the knife

0 · Reply

DARKP00L Jun. 3 at 11:31 AM

$COCP 07:02 on Jun. 03 2026 Cocrystal Pharma Appoints James Sapirstein As CEO, Effective Immediately #tradeideas

0 · Reply

SMTM_Plz Jun. 3 at 11:27 AM

$COCP https://www.stocktitan.net/sec-filings/COCP/8-k-cocrystal-pharma-inc-reports-material-event-2e5a52653fc3.html

0 · Reply

bulmar Jun. 2 at 7:18 PM

$COCP Martin still making money.

0 · Reply

DOUG_Called_It Jun. 2 at 2:40 PM

$COCP hey buddy, where you going? You coming down to me?

0 · Reply

DOUG_Called_It Jun. 1 at 10:22 PM

$COCP where you doing cocp? 😊

0 · Reply

Cocrystal co-CEOs Sam Lee and Jim Martin step down, James Sapirstein succeeds

Jun 3, 2026, 7:00 AM EDT - 1 day ago

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

2026-05-26T12:20:21.000Z - 9 days ago

Cocrystal Pharma announces discovery of pan-viral inhibitors targeting viruses

May 26, 2026, 8:00 AM EDT - 9 days ago

Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

May 15, 2026, 8:00 AM EDT - 20 days ago

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

Apr 30, 2026, 4:05 PM EDT - 5 weeks ago

Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection

2026-04-23T23:25:20.000Z - 6 weeks ago

Cocrystal Pharma files $150M mixed securities shelf

2026-04-02T12:22:27.000Z - 2 months ago

Cocrystal Pharma receives FDA Fast Track designation for CDI-988

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive

Mar 31, 2026, 8:00 AM EDT - 2 months ago

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

2026-03-09T12:10:09.000Z - 3 months ago

Cocrystal Pharma announces first subjects dosed in Phase 1b study of CDI-988

Mar 9, 2026, 8:00 AM EDT - 3 months ago

First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Feb 19, 2026, 8:00 AM EST - 3 months ago

Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

2025-12-18T13:16:41.000Z - 6 months ago

Cocrystal Pharma receives IRB approval from Emory University for Phase 1b trial

Dec 18, 2025, 8:00 AM EST - 6 months ago

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

Dec 1, 2025, 8:00 AM EST - 6 months ago

Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference

2025-11-14T13:11:15.000Z - 7 months ago

Cocrystal Pharma reports Q3 EPS (19c) vs (49c) last year

Nov 14, 2025, 8:00 AM EST - 7 months ago

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

2025-10-30T12:26:32.000Z - 7 months ago

Cocrystal Pharma completes $1.03M private placement

Oct 30, 2025, 8:00 AM EDT - 7 months ago

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules

2025-10-27T12:20:43.000Z - 7 months ago

Cocrystal Pharma receives NIH SBIR award to advance influenza inhibitor program

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

Oct 2, 2025, 8:00 AM EDT - 8 months ago

Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

2025-09-19T20:35:11.000Z - 9 months ago

Cocrystal Pharma files to sell 5.74M shares of common stock for holders

Sep 15, 2025, 4:30 PM EDT - 9 months ago

Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

2025-09-12T13:45:10.000Z - 9 months ago

Cocrystal Pharma announces up to $13M registered direct offering

Sep 12, 2025, 9:43 AM EDT - 9 months ago

Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

2025-09-12T12:10:38.000Z - 9 months ago

Cocrystal Pharma showcases CDI-988, antiviral for norovirus infection

Sep 12, 2025, 8:00 AM EDT - 9 months ago

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

2025-09-08T12:05:24.000Z - 9 months ago

Cocrystal Pharma receives IND clearance for challenge study of CDI-988

Sep 8, 2025, 8:00 AM EDT - 9 months ago

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

Sep 3, 2025, 8:00 AM EDT - 9 months ago

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

2025-08-14T12:15:44.000Z - 10 months ago

Cocrystal Pharma reports Q2 EPS (20c), consensus (30c)

Aug 14, 2025, 8:00 AM EDT - 10 months ago

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

2025-08-05T12:26:50.000Z - 10 months ago

Cocrystal Pharma presents Phase 1 results for CDI-988

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference

Jul 10, 2025, 8:00 AM EDT - 11 months ago

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

2025-06-20T10:10:30.000Z - 1 year ago

Cocrystal Pharma price target lowered to $6 from $7 at H.C. Wainwright

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference

2025-05-29T12:10:22.000Z - 1 year ago

Cocrystal announces CC-42344 active against 204 Texas H5N1 avian influenza

May 29, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

May 28, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference

2025-05-15T12:08:39.000Z - 1 year ago

Cocrystal Pharma reports Q1 EPS (23c) vs (39c) last year

May 15, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

2025-04-24T12:20:57.000Z - 1 year ago

Cocrystal Pharma’s norovirus oral candidate demonstrates ‘potent activity’

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 6, 2025, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

Dec 31, 2024, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Aug 19, 2024, 4:05 PM EDT - 1 year ago

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

Aug 15, 2024, 3:00 PM EDT - 1 year ago

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

May 13, 2024, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

May 1, 2024, 8:00 AM EDT - 2 years ago

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Mar 5, 2024, 8:30 AM EST - 2 years ago

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Dec 6, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Nov 29, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Nov 27, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Nov 9, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Apr 10, 2023, 8:30 AM EDT - 3 years ago

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

Jan 26, 2023, 8:00 AM EST - 3 years ago

Cocrystal Pharma Announces Participation in Virtual Investor Events

Jan 23, 2023, 9:00 AM EST - 3 years ago

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

Dec 1, 2022, 4:05 PM EST - 3 years ago

Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

Nov 17, 2022, 8:00 AM EST - 3 years ago

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

bulmar Jun. 4 at 7:22 PM

$COCP New CEO and MARTIN still employed watching precious shareholder money get spent. He’s good at that.

0 · Reply

ms101 Jun. 4 at 2:54 PM

$COCP New CEO just dropped. Hassan's 3.5-year stealth mission is now live. Rerate of the century loading....

0 · Reply

elon_musk22 Jun. 3 at 1:48 PM

$COCP Significant the move to $25 begins

0 · Reply

Mohamedkheer Jun. 3 at 1:43 PM

$COCP

1 · Reply

DOUG_Called_It Jun. 3 at 1:22 PM

$COCP only reason you appoint new ceo is because people are not getting result… don’t catch the knife

0 · Reply

DARKP00L Jun. 3 at 11:31 AM

$COCP 07:02 on Jun. 03 2026 Cocrystal Pharma Appoints James Sapirstein As CEO, Effective Immediately #tradeideas

0 · Reply

SMTM_Plz Jun. 3 at 11:27 AM

$COCP https://www.stocktitan.net/sec-filings/COCP/8-k-cocrystal-pharma-inc-reports-material-event-2e5a52653fc3.html

0 · Reply

bulmar Jun. 2 at 7:18 PM

$COCP Martin still making money.

0 · Reply

DOUG_Called_It Jun. 2 at 2:40 PM

$COCP hey buddy, where you going? You coming down to me?

0 · Reply

DOUG_Called_It Jun. 1 at 10:22 PM

$COCP where you doing cocp? 😊

0 · Reply

ZacksSCR Jun. 1 at 3:38 PM

$COCP: Presentation Highlights CDI-988 https://buff.ly/R5rfDju

0 · Reply

elon_musk22 May. 28 at 2:28 PM

$COCP Jai Wei busted owns 100 shares today so embarrassing #1 basher = Busted 🤣 love it its always the small ones now beat it old man

0 · Reply

bulmar May. 28 at 2:19 PM

$COCP Momo and his pumpers are gone again. They will reemerge from the toilet eventually. 💩

0 · Reply

elon_musk22 May. 27 at 11:49 PM

$COCP see you losers at $25 this summer

0 · Reply

elon_musk22 May. 27 at 11:45 PM

$COCP 215 ideas since 2020 another broke loser yeah you lost all your money move on BANKRUPT next

0 · Reply

WarrenMoonTradez May. 27 at 10:46 PM

$COCP “Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza” Nonsense! Any new virus on the news they will announce its name hoping to bring in new investors. DO NOT DO IT. SCAM!

0 · Reply

elon_musk22 May. 27 at 1:06 PM

$COCP Jai Wei exposed 🤡

0 · Reply

Channelchek May. 27 at 12:52 PM

Noble Capital Markets Research Report: Cocrystal Pharma ($COCP) – Technology Platform Has Novel Therapeutics Against Hantavirus, Bunyavirus, and Influenza Proprietary Technology Has Produced A Large Library Of Novel Antivirals. Cocrystal has developed a library of antivirals based on its proprietary technology. While clinical development has prioritized products with clear medical needs and regulatory pathways to approval, it continues to research new compounds that can be moved into development as public health needs change. Read full report here: https://www.channelchek.com/news-channel/cocrystal-pharma-cocp-technology-platform-has-novel-therapeutics-against-hantavirus-bunyavirus-and-influenza

2 · Reply

elon_musk22 May. 26 at 4:15 PM

$COCP Con man x Doug x fake wants you to think he has this massive short except he lost all his money after deleting his account below and is just a basher troll this is x Doug x aka = @ DOUG_Called_It the only thing he called is that he is bankrupt 🤣

0 · Reply

elon_musk22 May. 26 at 4:07 PM

$COCP this is x Doug x aka he deleted his old account = @ DOUG_Called_It all this fool does is pump and lose all his money like jai wei down 99%

0 · Reply

elon_musk22 May. 26 at 4:00 PM

$COCP "technical trader jai wei" if that was true this would have been sold 5 yrs ago but that was a lie Bull to Bagholder to basher troll Jai Wei doesn't want you to know 5 years ago 2000 shares at 25 now only a 200 left after splits and never sold beat it old man 🤡😭🤣

0 · Reply

Market Cap	14.61M
Revenue (ttm)	0.00
Net Income (ttm)	-8.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	200,800
Avg Vol	3,035,992
Day's Range	N/A - N/A
Shares Out	13.79M
Stochastic %K	13%
Beta	1.42
Analysts	Strong Sell
Price Target	$8.00